- TLDR Biotech
- Archive
- Page 2
The Latest Biotech & Pharma Updates
Biotech & Pharma Updates | November 24 - 25, 2025
🧬 AbbVie + adMare BioInnovations launch lab space award program for Quebec biotechs in key therapeutic areas, AstraZeneca's Imfinzi (durvalumab) lands FDA approval for perioperative gastric cancer and gastroesophageal junction cancer treatment, Novo Nordisk's amycretin shows competitive Ph2 weight loss results in type 2 diabetes patients, Zetagen Therapeutics raises $12.9M Series B1 for intratumoral treatments for breast cancer, Teva Pharmaceuticals receives European Commission approval for PONLIMSI and DEGEVMA (denosumab) biosimilars targeting bone conditions, Sarepta gets FDA approval to test immunosuppressive Elevidys regimen for non-ambulatory DMD patients
Biotech & Pharma Updates | November 23 - 24, 2025
🧬 Novartis receives FDA approval for Itvisma (onasemnogene abeparvovec-brve) gene therapy targeting spinal muscular atrophy in patients two years and older, Biogen + Dayra Therapeutics partner on oral macrocyclic peptides for immunology in $50M upfront plus milestones deal, MindImmune raises $30M Series A for inflammation-focused Alzheimer's therapy development, Phrontline Biopharma raises $60M Pre-A+ to develop bispecific and dual-payload ADCs, Kelun-Biotech's sacituzumab tirumotecan (sac-TMT) plus Merck & Co.’s Keytruda combo hits Ph3 endpoint in first-line non-small cell lung cancer, Gilead + Sprint Bioscience partner on TREX1 cancer program with $14M upfront + $400M biobucks, UK negotiates drug pricing deal with US - raising NHS cost-effectiveness thresholds for lower tariffs
Biotech & Pharma Updates | November 20 - 23, 2025
🧬 Eli Lilly becomes first pharmaceutical company to reach $1 trillion market valuation milestone, FDA approves Pfizer's Padcev and Merck & Co.'s Keytruda combo for perioperative muscle-invasive bladder cancer treatment, AstraZeneca invests $2B to expand Maryland manufacturing capacity and adding 300 jobs across two facilities, AGC Biologics + AAVantgarde manufacturing partnership for dual-vector gene therapies targeting inherited retinal disorders, Bayer's asundexian meets Ph3 endpoints for secondary stroke prevention Sorcero raises $42.5M Series B for AI-powered intelligence platform for life sciences, FDA to hire 1,000+ staff & launches communication program to accelerate drug review process
Biotech & Pharma Updates | November 19 - 20, 2025
🧬 Moderna secures $1.5B loan facility - targeting breakeven by 2028 amid pipeline reevaluation, Aspen Neuroscience raises $115M Series C for Parkinson's cell therapy development, Cassidy Bio launches with $8M seed funding to develop AI-driven gene editing platform, GSK + Quotient Therapeutics + ProFound Therapeutics partner on respiratory + liver disease targets in up to $7B potential deal value, Merck KGaA + Valo Health partner on Parkinson's target discovery using AI platform in up to $3B potential deal, Regeneron's Eylea HD wins FDA approval for retinal vein occlusion macular edema and monthly dosing expansion
Biotech & Pharma Updates | November 18 - 19, 2025
🧬 Eli Lilly opens fourth US Gateway Labs biotech incubator facility in Philadelphia, Novartis plans $771M North Carolina manufacturing hub expansion to add 700 jobs by 2028, Rafa Laboratories awarded $186M BARDA contract for intramuscular tranexamic acid injection development, Profluent raises $106M Series B, AI-driven protein design for therapeutics and agriculture, GSK + LTZ Therapeutics partner on myeloid cell engagers for cancer with $50M upfront, Bayer's Hyrnuo (sevabertinib) receives FDA accelerated approval targeting HER2-mutated non-small cell lung cancer, AstraZeneca + Sun Pharma partner to expand hyperkalaemia therapy access in India via dual branding, FDA grants full approval for Amgen's IMDELLTRA (tarlatamab) targeting extensive stage small cell lung cancer
Biotech & Pharma Updates | November 17 - 18, 2025
🧬 Regeneron invests $2B to convert former magazine factory into drug manufacturing plant in New York state, CSL pledges $1.5B investment to expand US plasma manufacturing capabilities over five years, Arrowhead Pharmaceuticals wins first FDA approval for Redemplo targeting familial chylomicronemia syndrome via RNA interference, Lifordi raises undisclosed strategic funding from Sanofi for ADC rheumatoid arthritis therapy, Vanda Pharmaceuticals' tradipitant (neurokinin-1 antagonist) reduces Wegovy-induced vomiting in Ph2 trial, Merck & Co.'s Winrevair (sotatercept) meets Ph2 endpoint for heart failure with preserved ejection fraction treatment, GSK + Fleming Initiative launch £45M ($59.2M) AI-powered antimicrobial resistance research partnership
Biotech & Pharma Updates | November 16 - 17, 2025
🧬 J&J acquires Halda Therapeutics for $3B cash to boost cancer pipeline toward $50B sales target, Solve Therapeutics raises $120M Series funding to advance ADC pipeline with novel linker technology, Artios Pharma raises $115M Series D to advance oncology pipeline including pancreatic/colorectal cancer treatments, Merus + Halozyme collaborate on subcutaneous petosemtamab formulation with upfront payment and royalties, Bayer officially opens Beijing incubator + names Puhe BioPharma and Youngen Technology as initial occupants, Jazz Pharmaceuticals' Ziihera (zanidatamab) hits Ph3 goals in HER2-positive gastroesophageal adenocarcinoma, FDA streamlines biosimilar approvals to cut $100M development costs though patent challenges remain
Biotech & Pharma Updates | November 13 - 16, 2025
🧬 Sofinnova Partners raises $750M flagship fund, early-stage biotech medtech investments, Medicxi closes $579M sixth fund for asset-centric biotech investing, Merck & Co. acquires Cidara Therapeutics for $9.2B to gain late-stage universal flu prevention drug CD388, Eisai presents 48-month lecanemab (leqembi) data showing sustained benefits in early Alzheimer's disease patients, FDA approves Henlius' Poherdy (pertuzumab-dpzb) - first interchangeable biosimilar to Roche's Perjeta for HER2-positive breast cancer, PRISM BioLab achieves initial milestone + milestone payment in oncology drug discovery collaboration with Ono Pharmaceutical using PepMetics technology
Biotech & Pharma Updates | November 12 - 13, 2025
🧬 Pfizer officially closes $9.2 billion Metsera acquisition after winning bidding war against Novo Nordisk, T-Therapeutics raises $91M Series A extension to advance TCR-CD3 bispecifics for cancer/autoimmune, 4TEEN4 raises €55M ($63.75M) Series C for cardiogenic shock antibody procizumab development, Third Arc Bio + Adagene partner on cancer T cell engagers using SAFEbody technology - $5M upfront + $840M biobucks, Day One acquires struggling ADC developer Mersana for $129M upfront in milestone-heavy deal, Kura Oncology's Komzifti (ziftomenib) receives FDA approval for NPM1-mutant acute myeloid leukemia treatment
Biotech & Pharma Updates | November 11 - 12, 2025
🧬 ABL Bio + Eli Lilly partner on blood-brain barrier platform with $40M upfront + $2.562B biobucks, Indivi raises CHF15M ($18.7M) to determine precision medicine biomarkers for Alzheimer's drug development, Syrna Therapeutics emerges from stealth with covalent translation inhibitors targeting disease-causing mRNA proteins, Novartis plans approval filing for GanLum malaria drug following Ph3 success in parasitic infection treatment, Alkermes reports Ph2 success for alixorexton targeting orexin 2 receptor in narcolepsy type 2 - advancing to Ph3, Novo Nordisk slashes Wegovy weight-loss drug prices up to 33% in India amid increased competition